Bupropion in depression: a tri-center placebo-controlled study.

Area of Science:

• Psychiatry
• Clinical Pharmacology

Background:

• Depression is a prevalent and debilitating mental health condition requiring effective treatment options.
• Nonpsychotic depression presents unique challenges in therapeutic management.

Purpose of the Study:

• To evaluate the efficacy and safety of bupropion compared to placebo in hospitalized patients with nonpsychotic depression.
• To determine the onset of action and identify patient subgroups who benefit most from bupropion treatment.

Main Methods:

• A double-blind, placebo-controlled, variable-dose study.
• Involved 59 hospitalized patients diagnosed with nonpsychotic depression.
• Assessed depression, anxiety, and global improvement using validated measures.

Main Results:

• Bupropion showed statistically significant improvements in depression, anxiety, and global functioning compared to placebo (p < .05 to < .001).
• Efficacy differences emerged by day 5 and increased over time.
• Bupropion was particularly effective in patients with more severe depression.
• Adverse events were similar between groups, with mild dry mouth being the most common (20%).

Conclusions:

• Bupropion is an effective treatment for nonpsychotic depression in hospitalized patients.
• The medication offers a favorable safety profile with manageable side effects.
• Early onset of action and efficacy in severe depression highlight bupropion's therapeutic potential.